Lexicon Pharma (LXRX) Tops Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.31 -0.43%
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $15.86 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Redwood Trust reports record Aspire quarter, launches AI pricing tools
- UBS Reiterates Buy Rating on Smurfit Westrock (SW)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
